Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 14/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.64 |
| ▸ | ABL1 | P00519 | 3/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | CLK1 | P49759 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3404307 | 0.92 | MET (0.54) | METCYP3A4ABL1 | |
| SCHEMBL2799672 | 0.90 | ABL1 (0.60) | METCYP3A4ABL1POLBALDH1A1 | |
| SCHEMBL6068309 | 0.86 | ABL1 (0.65) | METCYP3A4ABL1HTTCLK1 | |
| SCHEMBL2763569 | 0.85 | MET (0.59) | METCYP3A4ABL1HTTCLK1 | |
| SCHEMBL3410979 | 0.85 | MET (0.48) | METCYP3A4ABL1SMN1; SMN2 | |
| SCHEMBL543789 | 0.84 | ABL1 (0.69) | METCYP3A4ABL1HTTCLK1 | |
| SCHEMBL613934 | 0.84 | ABL1 (0.69) | METCYP3A4ABL1HTTCLK1 | |
| SCHEMBL3408197 | 0.82 | SMN1; SMN2 (0.62) | HTTCLK1SMN1; SMN2MEN1POLB | |
| SCHEMBL15415720 | 0.80 | ABL1 (0.70) | METCYP3A4ABL1SMN1; SMN2 | |
| SCHEMBL6068007 | 0.79 | ABL1 (0.60) | ABL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9321777-B2 | 6-triazolopyridazine sulfanyl benzothiazole derivatives as MET inhibitors | SANOFI (FR) | 2016-04-26 | — | — | US | disclosed |
| US-20150344484-A1 | NOVEL 6-TRIAZOLOPYRIDAZINE SULFANYL BENZOTHIAZOLE DERIVATIVES AS MET INHIBITORS | SANOFI-AVENTIS (FR) | 2015-12-03 | — | — | US | disclosed |
| US-9115134-B2 | 6-triazolopyridazine sulfanyl benzothiazole derivatives as MET inhibitors | SANOFI (FR) | 2015-08-25 | — | — | US | disclosed |
| US-20140005189-A1 | NOVEL 6-TRIAZOLOPYRIDAZINE SULFANYL BENZOTHIAZOLE DERIVATIVES AS MET INHIBITORS | SANOFI (FR) | 2014-01-02 | — | — | US | disclosed |
| US-8546393-B2 | 6-triazolopyridazine sulfanyl benzothiazole derivatives as MET inhibitors | SANOFI (FR) | 2013-10-01 | — | — | US | disclosed |
| US-20120040987-A1 | DERIVATIVES OF 6-(6-NH-SUBSTITUTED-TRIAZOLOPYRIDAZINE-SULFANYL) BENZOTHIAZOLES AND BENZIMIDAZOLES, PREPARATION THEREOF, USE THEREOF AS DRUGS, AND USE THEREOF AS MET INHIBITORS | SANOFI (FR) | 2012-02-16 | — | — | US | disclosed |
| US-20110263593-A1 | NOVEL IMIDAZO[1,2-a]PYRIMIDINE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE, IN PARTICULAR AS MET INHIBITORS | SANOFI-AVENTIS (FR) | 2011-10-27 | — | — | US | disclosed |
| US-20110257171-A1 | NOVEL IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS MET INHIBITORS | SANOFI-AVENTIS (FR) | 2011-10-20 | — | — | US | disclosed |
| US-20100298315-A1 | NOVEL 6-TRIAZOLOPYRIDAZINESULFANYL BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND APPLICATION AS MEDICAMENTS AND PHARMNACEUTICAL COMPOSITIONS AND NOVEL USE AS MET INHIBITORS | SANOFI-AVENTIS (FR) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344484-A1 | NOVEL 6-TRIAZOLOPYRIDAZINE SULFANYL BENZOTHIAZOLE DERIVATIVES AS MET INHIBITORS | MET, TPMT, MERTK | MET 1/4885CYP3A4 224/4885ABL1 8/4885 |
| US-20140005189-A1 | NOVEL 6-TRIAZOLOPYRIDAZINE SULFANYL BENZOTHIAZOLE DERIVATIVES AS MET INHIBITORS | MET, TPMT, MERTK | MET 1/4885CYP3A4 224/4885ABL1 8/4885 |
| US-20120040987-A1 | DERIVATIVES OF 6-(6-NH-SUBSTITUTED-TRIAZOLOPYRIDAZINE-SULFANYL) BENZOTHIAZOLES AND BENZIMIDAZOLES, PREPARATION THEREOF, USE THEREOF AS DRUGS, AND USE THEREOF AS MET INHIBITORS | MET, NR1I2, NCOR2 | MET 1/4885CYP3A4 127/4885ABL1 573/4885 |
| US-20110257171-A1 | NOVEL IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS MET INHIBITORS | MET, ALK, RET | MET 1/4885CYP3A4 73/4885ABL1 43/4885 |
| US-20100298315-A1 | NOVEL 6-TRIAZOLOPYRIDAZINESULFANYL BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND APPLICATION AS MEDICAMENTS AND PHARMNACEUTICAL COMPOSITIONS AND NOVEL USE AS MET INHIBITORS | BMX, MET, TPMT | MET 2/4885CYP3A4 47/4885ABL1 20/4885 |
| US-20110263593-A1 | NOVEL IMIDAZO[1,2-a]PYRIMIDINE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE, IN PARTICULAR AS MET INHIBITORS | TPMT, MET, PAICS | MET 2/4885CYP3A4 173/4885ABL1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.